TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10655967
Drug: Spinach meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinach meal (300 g/d)
Study: 10655967
Drug: Beta-carotene supplemented
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplemented meal (33.3 mg)
Study: 10655967
Drug: Broccoli and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli and green peas (per mg carotenoid consumed)
Study: 29863280
Drug: DWP14012 (20-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 (20-160 mg once daily for 7 days)
Study: 26822418
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) combined with physical therapy
Study: 30917125
Drug: PRS-080#22 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRS-080#22 (doses 0.08-16 mg/kg for healthy volunteers, 2-8 mg/kg for CKD patients)
Study: 14758145
Drug: rPAF‐AH 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: rPAF‐AH 1.0 mg/kg intravenously once daily for five consecutive days
Study: 9253907
Drug: Oxandrolone +
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone + high-protein diet (2 g/kg/day)
Study: 9253907
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet alone (2 g/kg/day)
Study: 9253907
Drug: Retrospective group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective group (high-calorie, high-protein diet with 1.3 to 1.4 g/kg/day)
Study: 29862410
Drug: Tart cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart cherry juice (480 ml daily for 12 weeks)
Study: 21882288
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment for depression (psychotherapy plus antidepressants)
Study: 21882288
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (antidepressants alone)
Study: 11579009
Drug: Drug-free comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free comparison group
Study: 31326319
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg twice a day for 12 weeks
Study: 19090788
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering therapy with atorvastatin
Study: 19090788
Drug: Moderate lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate lipid-lowering therapy with pravastatin
Study: 11033746
Drug: Preparation for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation for Parenthood groups (psychosocial intervention)
Study: 8170484
Drug: Deflazacort 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort 2.0 mg/kg alternate-day therapy
Study: 3046332
Drug: Cyclosporine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (5 mg/kg/d)
Study: 20554506
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment initially)
Study: 12898459
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) treatment
Study: 18004131
Drug: Flunitrazepam (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1.25 mg)
Study: 16647412
Drug: Plant stanols
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanols (2.0 g daily in low-fat yogurt)
Study: 10793592
Drug: MIKE (ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIKE (ketamine 3 mg kg‐1, midazolam 0.5 mg kg‐1)
Study: 1431767
Drug: Particles-in-tablet form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particles-in-tablet form of erythromycin (333 mg three times daily for 10 days)
Study: 1431767
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (400 mg four times daily for 10 days)
Study: 20299634
Drug: Antibiotic pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic pretreatment
Study: 27424011
Drug: Liquefied ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Liquefied ibuprofen 400 mg
Study: 22947225
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (500 mg DHA + 150 mg EPA, 400 μg 5-methyltetrahydrofolate)
Study: 20827544
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (cannulated screw fixation with postoperative splint immobilization for a maximum of 1 week)
Study: 29471679
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg erenumab
Study: 25491514
Drug: Dental health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental health education by qualified dentists and school teachers with supply of oral hygiene aids
Study: 25491514
Drug: Dental health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental health education by qualified dentists and school teachers without supply of oral hygiene aids
Study: 17469045
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg) for two weeks
Study: 12433510
Drug: Subcutaneous melagatran
Normalized name: melagatran
DrugBank: Melagatran (DB13616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous melagatran followed by oral ximelagatran (dose categories: 1.00 mg, 1.50 mg, 2.25 mg, or 3.00 mg twice daily; followed by 8 mg, 12 mg, 18 mg, or 24 mg twice daily)
Study: 12433510
Drug: Subcutaneous dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dalteparin 5000 IU once daily
Study: 9818340
Drug: Oral acetazolamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetazolamide, 500 mg 1 hour preoperatively
Study: 9818340
Drug: Oral acetazolamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetazolamide, 500 mg immediately postoperatively
Study: 7851351
Drug: Fentanyl (induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (induction 10 micrograms kg‐1 plus infusion 10 micrograms kg‐1 h‐1)
Study: 4164930
Drug: Indomethacin (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (doses above 150 mg per day)
Study: 28950430
Drug: ADA +
Normalized name: Adenosine deaminase
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADA + MTX combination therapy
Study: 28298244
Drug: Manual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual administration of anesthetics guided by BIS sensor
Study: 28298244
Drug: Automated administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated administration of anesthetics
Study: 12869078
Drug: Tioguanine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tioguanine (40 mg tablet preparation)
Study: 8678493
Drug: Endocrine therapies
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapies
Study: 29402141
Drug: Tirasemtiv (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirasemtiv (various doses)
Study: 24535455
Drug: Rikkunshito (RKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rikkunshito (RKT) + rabeprazole (10 mg/day) for 8 weeks
Study: 24535455
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + rabeprazole (10 mg/day) for 8 weeks
Study: 16216469
Drug: Ceftriaxone (CRO)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (CRO) 100mg/kg once daily
Study: 2108852
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with thrombolytic therapy
Study: 16981054
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy alone
Study: 30606246
Drug: Intramuscular oxytocin/ergometrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular oxytocin/ergometrine
Study: 30606246
Drug: Intramuscular carbetocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular carbetocin
Study: 22924356
Drug: Articaine 4%
Normalized name: ARTICAINE 4%/EPI 1:200000 INJ CART 1.7ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine 4% with 1:100 000 adrenaline delivered via Buccal Infiltration (BI)
Study: 19622592
Drug: Corticosteroid eyedrops
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid eyedrops (CS), administered six times daily during docetaxel administration
Study: 19622592
Drug: Artificial tears
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears (AT), administered six times daily during docetaxel administration
Study: 18068062
Drug: Air group
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air group (n = 26) - distal cuff inflated with 2 mL of air
Study: 18068062
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group (n = 26) - distal cuff inflated with 1.2 mL of saline
Study: 1085738
Drug: Flufenamic acid
Normalized name: Flufenamic acid
DrugBank: Flufenamic acid (DB02266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flufenamic acid ointment (Mobilisin)
Study: 21878747
Drug: Functional electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional electrical therapy
Study: 19332192
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (specifics not provided)
Study: 17130515
Drug: Chemotherapy-induced amenorrhea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-induced amenorrhea
Study: 10551494
Drug: E2F-decoy treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2F-decoy treatment
Study: 10551494
Drug: Scrambled-oligodeoxynucleotide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scrambled-oligodeoxynucleotide treatment
Study: 8728041
Drug: Home total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home total parenteral nutrition (TPN; n = 16)
Study: 1653362
Drug: CPT-11 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 at weekly doses of 100 mg/m2
Study: 1653362
Drug: CPT-11 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 at weekly doses ranging from 50 to 150 mg/m2
Study: 1653362
Drug: CPT-11 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 at weekly doses
Study: 6218370
Drug: CI2MDP 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI2MDP 1600 mg/d
Study: 30846304
Drug: l-isoproterenol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-isoproterenol (10 μg/kg/h)
Study: 30846304
Drug: salbutamol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol (500 μg/kg/h)
Study: 11236045
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml sucrose 24% w/v
Study: 9593779
Drug: Enteral feeding
Normalized name: enteral feeding dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral feeding plus exogenous insulin (200 pmol/h = 28 U/h) with extra glucose as needed (I+G)
Study: 8534671
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg daily simvastatin
Study: 8534671
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg daily simvastatin
Study: 21782470
Drug: Unguided injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided injection
Study: 30012233
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list (treatment as usual)
Study: 16546598
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate lotion 0.05% applied once daily for 4 weeks
Study: 16546598
Drug: Placebo lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lotion applied once daily for 4 weeks
Study: 12778391
Drug: Standard or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard or high-dose cisplatin with etoposide and bleomycin
Study: 12778391
Drug: Cisplatin dose
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin dose comparison
Study: 8103526
Drug: S-timolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-timolol (0.5 mg, 1 mg)
Study: 8103526
Drug: R-timolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-timolol (3 mg, 10 mg)
Study: 8103526
Drug: S-timolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-timolol (1 mg, 3 mg)
Study: 8103526
Drug: R-timolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-timolol (25 mg, 75 mg)
Study: 29724663
Drug: High-dose venlafaxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose venlafaxine with supportive management for 10 weeks
Study: 15728057
Drug: Morphine (M-large)
Normalized name: morphine sulfate Extended Release Oral Capsule [M-Eslon]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (M-large) 0.43 mg/kg
Study: 16368813
Drug: Morphine (M-small)
Normalized name: morphine sulfate Extended Release Oral Capsule [M-Eslon]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (M-small) 0.11 mg/kg
Study: 12856052
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with mebendazole and levamisole
Study: 31030379
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (660 nm, 100 mW, 2 J, 66.66 J/cm2, 3.3 W/cm2, 20 s of irradiation, punctual, and continuous mode)
Study: 27220593
Drug: Pulmonary artery
Normalized name: Pulmonary artery blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary artery pressure-guided management (treatment group)
Study: 27220593
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (symptoms and daily weights alone)
Study: 16192511
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL anesthetic solution
Study: 16192511
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (3 mL and 5 mL)
Study: 4065432
Drug: Poor metabolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor metabolic control (median blood glucose 16.3 mmol/L)
Study: 27281084
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 5 mg
Study: 8937760
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (desogestrel+ethinyloestradiol)
Study: 8937760
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (levonorgestrel and ethinyloestradiol)
Study: 3096681
Drug: Diazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (20 mg) + Methadone (150% of maintenance dose)
Study: 3096681
Drug: Diazepam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (40 mg) + Methadone (150% of maintenance dose)
Study: 3096681
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Methadone (100% of maintenance dose)
Study: 29222891
Drug: Glucose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (50 g/278 mL, p.o.) 2 h before anaesthesia induction
Study: 27219115
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (once daily for 5 consecutive days starting on postoperative day 1, at 16 acupoints)
Study: 27219115
Drug: Nonacupuncture (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonacupuncture (no treatment)
Study: 25481809
Drug: Various OA
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various OA treatments (pharmacological and non-pharmacological)
Study: 25481809
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy for knee OA
Study: 25481809
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy for hip OA
Study: 18025524
Drug: Peptidic erythropoiesis
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptidic erythropoiesis receptor agonist at doses of 0.025, 0.05, and 0.1 mg/kg
Study: 18025524
Drug: Peptidic erythropoiesis
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptidic erythropoiesis receptor agonist
Study: 9460311
Drug: Expectant management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectant management followed by induction with prostaglandin E2 gel
Study: 3317352
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms dose per injection
Study: 27283332
Drug: Tapering csDMARDs
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering csDMARDs
Study: 27283332
Drug: Tapering bDMARDs
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering bDMARDs
Study: 19186857
Drug: Conventional root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional root canal therapy (conventional therapy group)
Study: 6782606
Drug: Secobarbital 1.47
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital 1.47 mg/kg
Study: 6782606
Drug: Secobarbital 2.94
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital 2.94 mg/kg
Study: 15530692
Drug: Connaught high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Connaught high titer vaccine (CN)
Study: 12578106
Drug: Rocuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium administered within 1‐15 seconds
Study: 12578106
Drug: Rocuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium administered within 30‐60 seconds
Study: 26542030
Drug: Any treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment (including chemotherapy, surgery, or radiotherapy)
Study: 26542030
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment (surgery and/or radiotherapy)
Study: 22925988
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate 5 to 10 mg once daily
Study: 22925988
Drug: S(‐)‐amlodipine nicotinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(‐)‐amlodipine nicotinate 2.5 to 5 mg once daily
Study: 12743773
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with lansoprazole (LPZ), amoxicillin (AMPC), and clarithromycin (CAM) for 7 days
Study: 2753406
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g lactulose (L) with 20 mg metoclopramide (M)
Study: 16000666
Drug: Bioabsorbable poly-l-lactic
Normalized name: L-Lactic acid
DrugBank: L-Lactic acid (DB14475)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable poly-l-lactic acid screws
Study: 2294875
Drug: Quantitative fluorometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative fluorometry with intravenous fluorescein administration before amputation
Study: 26871828
Drug: Clinical medicine-unrelated
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical medicine-unrelated topics
Study: 26871828
Drug: Clinical medicine-related
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical medicine-related topics
Study: 25015649
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (Se) during radiation therapy
Study: 17939262
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg IV q24h followed by 500 mg orally q24h
Study: 17939262
Drug: Amoxicillin/clavulanate 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 500 mg/100 mg IV q8h with oral clarithromycin 500 mg q12h, then oral amoxicillin/clavulanate 250 mg/125 mg q8h with oral clarithromycin 500 mg q12h
Study: 11973187
Drug: Acetaminophen 2000
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 2000 mg and Celecoxib 200 mg
Study: 1745622
Drug: Acetaminophen 2000
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 2000 mg
Study: 11973187
Drug: Placebo (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Vitamin C, 500 mg)
Study: 7859695
Drug: Spaghetti without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spaghetti without paracetamol
Study: 2808056
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (prostate vs. prostate and pelvic lymph nodes)
Study: 1020682
Drug: Oral dexetimide
Normalized name: dexetimide
DrugBank: Dexetimide (DB08997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexetimide (0.5 to 1.5 mg daily)
Study: 1020682
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with antiparkinsonian agents)
Study: 27847124
Drug: Passive robotic‐assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive robotic‐assisted hand motion using the Gloreha device, twice a day for 2 weeks
Study: 25890874
Drug: Vitamins E
Normalized name: Multiple Vitamins Essentials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins E (α‐[600 mg RRR‐α‐tocopherol, αT] and γ‐[600 mg of RRR‐γT]) and C (1000 mg ascorbic acid, AA)